Send me a link:

*Text messaging rates may apply.

 Dow Up0.15% Nasdaq Up0.41%

Peregrine Pharmaceuticals, Inc. (PPHM)

1.76 Up 0.05(2.92%) 3:52PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin, CA 92780
United States - Map
Phone: 714-508-6000
Fax: 714-838-5817

Index Membership:N/A
Full Time Employees:182

Business Summary 

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of monoclonal antibodies focused on the treatment and diagnosis of cancer. The company’s lead product candidates in development include Bavituximab, a phosphatidylserine (PS) targeting agent that completed Phase IIb second-line non-small cell lung cancer trial for the treatment of solid tumors; and Cotara, a DNA/histone-targeting antibody that completed Phase II multicenter trial for the treatment of brain cancer. It is also conducting various other trials with bavituximab in combination with other therapies in multiple oncology indications as potential secondary indications for bavituximab; and an open-label single-center clinical trial under an exploratory investigational new drug application filed with the FDA for its lead imaging agent 124I-PGN650 for the imaging of multiple solid tumor types. In addition, the company, through its subsidiary, Avid Bioservices, Inc., provides various contract biomanufacturing services that support the development and current good manufacturing practices (cGMP) production of clinical and commercial monoclonal antibodies, and recombinant proteins and enzymes, including cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has license, research, and development agreements with the University of Texas Southwestern Medical Center; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; UTSWMC; and Merck KGaA. The company was founded in 1981 and is based in Tustin, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Peregrine Pharmaceuticals, Inc.

Corporate Governance 
Peregrine Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 9; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Steven W. King , 50
Chief Exec. Officer, Pres, Director, Chief Exec. Officer of Avid Bioservices Inc and Pres of Avid Bioservices Inc
Mr. Paul J. Lytle CPA, 46
Chief Financial Officer, Principal Accounting Officer, Corp. Sec., Chief Financial Officer of Avid Bioservices Inc and Corp. Sec. of Avid Bioservices Inc
Mr. Mark R. Ziebell J.D., 50
VP, Gen. Counsel and Corp. Sec.
Dr. Shelley P. M. Fussey Ph.D., 48
VP of Intellectual Property
Mr. Joseph S. Shan M.P.H., 41
VP of Clinical & Regulatory Affairs
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders